SGX Pharmaceuticals Reports Toxicity With Lead Oncology Candidate In Phase I
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Grey acknowledges setback but points to second MET inhibitor and Novartis-partnered BCR-ABL inhibitor program as promising.
You may also be interested in...
Lilly FASTens On SGX Following Shareholder Vote To Complete Acquisition
Lilly acquires SGX, with its “FAST” fragment-based drug discovery platform and preclinical oncology portfolio; new subsidiary can move beyond financial woes.
Lilly FASTens On SGX Following Shareholder Vote To Complete Acquisition
Lilly acquires SGX, with its “FAST” fragment-based drug discovery platform and preclinical oncology portfolio; new subsidiary can move beyond financial woes.
Lilly Buying SGX For $64M In Cash
2003 partnership turns into takeover for structural biology firm.